18 Subsequent Events	12 Months Ended
Jun. 30, 2015
Notes
18 Subsequent Events	18 SUBSEQUENT EVENTS On July 23, 2015, the Company entered into a loan agreement with Postal Savings Bank of China and obtained a loan of RMB27 million (approximately $4.4 million) with a term of five months maturing on December 22, 2015. This loan bears an annual interest rate of 7.8%. On July 10, 2015 and on October 9, 2015, the Company obtained extensions of the short term borrowing from Shijiazhuang Construction Investment Group. $3,100,117 was due on July 12, 2015 and was extended to October 27, 2015 and then further extended to April 26, 2016. $1,957,969 was due on October 25, 2015 and was extended to April 24, 2016. The loans bear an annual interest rate of 12%. On September 17, 2015, the Company extended the six-month term loan of $3,263,282 from Hebei Henghui Investment Management Co., Ltd. to October 17, 2015. On September 30, 2015, the Company repaid $656,250 of the loan and the remainder of the loan was extended to April 16, 2016. The loan was originally due on September 17, 2015 and bears an annual interest rate of 10%. On September 30, 2015 the Company sold 2,352,941 shares of common stock and 1,764,706 common stock purchase warrants (the "Public Warrants") pursuant to a Securities Purchase Agreement dated as of September 24, 2015. The purchaser was an institutional investor. The aggregate purchase price for the securities was $3,000,000. From the proceeds of the offering, the Company paid a fee of $180,000 to the placement agent for the offering. Aoxing Pharmaceutical Company, Inc. has also issued to the placement agent and its affiliates warrants to purchase 141,176 shares of common stock. Each Public Warrant will permit the holder to purchase one share of common stock from the Company for a price of $1.74 per share. The Public Warrants will be exercisable from March 30, 2016 until March 30, 2021. The warrants issued to the placement agent and its affiliates are substantially identical to the Public Warrants, except that the termination date is September 24, 2020. Cashless exercise of either warrant is permitted only if there is no effective registration statement permitting resale of the common shares underlying the warrants. In accordance with ASC 855 “Subsequent Events”, which establishes general standards of accounting for and disclosure of events that occur after the balance sheet date but before financial statements are issued, we have evaluated all events or transactions that occurred after June 30, 2015up through the date we issued the consolidated financial statements and has determined that there was no other material event that occurred after the date of the balance sheets included in this report.

18 Subsequent Events

12 Months Ended

Jun. 30, 2015

18 SUBSEQUENT EVENTS

On July 23, 2015, the Company entered into a loan agreement with Postal Savings Bank of China and obtained a loan of RMB27 million (approximately $4.4 million) with a term of five months maturing on December 22, 2015. This loan bears an annual interest rate of 7.8%.

On July 10, 2015 and on October 9, 2015, the Company obtained extensions of the short term borrowing from Shijiazhuang Construction Investment Group. $3,100,117 was due on July 12, 2015 and was extended to October 27, 2015 and then further extended to April 26, 2016. $1,957,969 was due on October 25, 2015 and was extended to April 24, 2016. The loans bear an annual interest rate of 12%.

On September 17, 2015, the Company extended the six-month term loan of $3,263,282 from Hebei Henghui Investment Management Co., Ltd. to October 17, 2015. On September 30, 2015, the Company repaid $656,250 of the loan and the remainder of the loan was extended to April 16, 2016. The loan was originally due on September 17, 2015 and bears an annual interest rate of 10%.

On September 30, 2015 the Company sold 2,352,941 shares of common stock and 1,764,706 common stock purchase warrants (the "Public Warrants") pursuant to a Securities Purchase Agreement dated as of September 24, 2015. The purchaser was an institutional investor. The aggregate purchase price for the securities was $3,000,000. From the proceeds of the offering, the Company paid a fee of $180,000 to the placement agent for the offering. Aoxing Pharmaceutical Company, Inc. has also issued to the placement agent and its affiliates warrants to purchase 141,176 shares of common stock. Each Public Warrant will permit the holder to purchase one share of common stock from the Company for a price of $1.74 per share. The Public Warrants will be exercisable from March 30, 2016 until March 30, 2021. The warrants issued to the placement agent and its affiliates are substantially identical to the Public Warrants, except that the termination date is September 24, 2020. Cashless exercise of either warrant is permitted only if there is no effective registration statement permitting resale of the common shares underlying the warrants.

In accordance with ASC 855 “Subsequent Events”, which establishes general standards of accounting for and disclosure of events that occur after the balance sheet date but before financial statements are issued, we have evaluated all events or transactions that occurred after June 30, 2015up through the date we issued the consolidated financial statements and has determined that there was no other material event that occurred after the date of the balance sheets included in this report.